2-(苄氧基)-5-溴苯甲酸甲酯 | 860000-78-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(苄氧基)-5-溴苯甲酸甲酯
• 英文名称: methyl 2-(benzyloxy)-5-bromobenzoate
• 英文别名: methyl 5-bromo-2-phenylmethoxybenzoate
• CAS: 860000-78-8
• 化学式: C₁₅H₁₃BrO₃
• 分子量: 321.17
• InChiKey: AXWGWAJAENITOC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  35.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  2-(苄氧基)-5-溴苯甲酸甲酯 在 palladium diacetate 、 三溴化硼 、 三(邻甲基苯基)磷 作用下， 以 二氯甲烷 、 三乙胺 为溶剂， 反应 19.0h， 生成 ethyl (E)-3-carbomethoxy-4-hydroxycinnamate
  参考文献：
  名称：

  Analogues of Orphan Nuclear Receptor Small Heterodimer Partner Ligand and Apoptosis Inducer (E)-4-[3-(1-Adamantyl)-4-hydroxyphenyl]-3-chlorocinnamic Acid. 2. Impact of 3-Chloro Group Replacement on Inhibition of Proliferation and Induction of Apoptosis of Leukemia and Cancer Cell Lines

  摘要：

  The parent phenol of adapalene and its (E)-cinnamic acid analogue were found to induce cancer cell apoptosis but cause adverse systemic effects when administered to mice. In contrast, their respective 5-Cl- and 3-Cl-substituted analogues had their adverse effects mitigated without a comparable loss of cancer cell inhibitory activity. As a result, pharmacologic space in this region of the cinnamic phenyl ring scaffold was explored. Various substituents were introduced, and their effects on cancer, cell proliferation and viability were evaluated. Cinnamic acids having 3-Br, CN, NO2, NH2, OMe, and N-3 groups had activity comparable to that of 4-[3'-(1-adamantyl)-4'-hydroxyphenyl]-3-chlorocinnamic acid. A comparative molecular field analysis study indicated that introduction of an H-bond acceptor at position 3 of the central phenyl ring would favor inhibition of leukemia cell viability, and docking suggested its hydrogen bonding with a polar group in a small heterodimer partner homology model. The 3-CN, NO2, NH2, and OH analogues also inhibited MMTV-Wnt1 murine mammary stem cell viability.

  DOI：

  10.1021/jm2011436
• 作为产物：
  描述：

  5-溴水杨酸甲酯 、 溴甲苯 在 potassium carbonate 、 potassium iodide 作用下， 以 丙酮 为溶剂， 生成 2-(苄氧基)-5-溴苯甲酸甲酯
  参考文献：
  名称：

  通过PhI（OAc）2介导的级联螺旋环化无金属合成Spiro-2,2'-苯并[ b ]呋喃-3,3'-酮

  摘要：

  在室温下仅用PhI（OAc）2（PIDA）在室温下仅用PhI（OAc）2（PIDA）处理苄基保护的3-羟基-1,3-双（2-羟基苯基）丙-2-烯-1-酮很容易提供很少研究的spiro-2 ，2'-苯并[b]呋喃-3,3'-酮类产品具有令人满意的优异收率。高价碘试剂可实现无金属级联螺环化，从而形成双氧化C-O键。

  DOI：

  10.1002/adsc.201900652

文献信息

• [EN] TRIAZOLONE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS DE TRIAZOLONE ET LEURS UTILISATIONS
  申请人：INCEPTION 2 INC

  公开号：WO2014099503A1

  公开（公告）日：2014-06-26

  The invention disclosed herein is directed to compounds of Formula I [Formula should be inserted here] and pharmaceutically acceptable salts thereof, which are useful in the treatment of prostate, breast, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention also comprises pharmaceutical compositions comprising a therapeutically effective amount of compound of Formula I, or a pharmaceutically acceptable salt thereof. The invention disclosed herein is also directed to methods of treating prostate, breast, ovarian, liver, kidney, colon, pancreatic, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein is further directed to methods of treating prostate, breast, colon, pancreatic, chronic lymphocytic leukemia, melanoma and other cancers comprising administration of a therapeutically effective amount of a selective PPARa antagonist. The compounds and pharmaceutical compositions of the invention are also useful in the treatment of viral infections, such as HCV infections and HIV infections.

  本发明涉及式I的化合物[应在此处插入公式]及其药学上可接受的盐，用于治疗前列腺、乳腺、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症。该发明还包括含有式I化合物的治疗有效量或其药学上可接受的盐的药物组合物。本发明还涉及治疗前列腺、乳腺、卵巢、肝脏、肾脏、结肠、胰腺、人类慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法。本发明还涉及治疗前列腺、乳腺、结肠、胰腺、慢性淋巴细胞白血病、黑色素瘤和其他癌症的方法，包括给予选择性PPARa拮抗剂的治疗有效量。该发明的化合物和药物组合物还可用于治疗病毒感染，如HCV感染和HIV感染。
• Metal‐free Synthesis of Spiro‐2,2′‐benzo[ <i>b</i> ]furan‐3,3′‐ones <i>via</i> PhI(OAc) ₂ ‐Mediated Cascade Spirocyclization
  作者：Qingyu Xing、Huiyuan Liang、Mingmai Bao、Xuemin Li、Jingran Zhang、Tianhao Bi、Yilin Zhang、Jun Xu、Yunfei Du、Kang Zhao

  DOI：10.1002/adsc.201900652

  日期：2019.10.22

  Treating the benzyl protected 3‐hydroxy‐1,3‐bis(2‐hydroxyphenyl)prop‐2‐en‐1‐ones solely with PhI(OAc)2 (PIDA) in DCE at room temperature readily furnished the seldom studied spiro‐2,2′‐benzo[b]furan‐3,3′‐ones in satisfactory to excellent yields. The hypervalent iodine reagent enables the metal‐free cascade spirocyclization resulting in the dual oxidative C−O bond formation.

  在室温下仅用PhI（OAc）2（PIDA）在室温下仅用PhI（OAc）2（PIDA）处理苄基保护的3-羟基-1,3-双（2-羟基苯基）丙-2-烯-1-酮很容易提供很少研究的spiro-2 ，2'-苯并[b]呋喃-3,3'-酮类产品具有令人满意的优异收率。高价碘试剂可实现无金属级联螺环化，从而形成双氧化C-O键。
• [EN] SELECTIVE ESTROGEN RECEPTOR MODULATORS<br/>[FR] MODULATEURS SELECTIFS DU RECEPTEUR DES OESTROGENES
  申请人：LILLY CO ELI

  公开号：WO2005073205A1

  公开（公告）日：2005-08-11

  The present invention relates to a selective estrogen receptor modulators of formula I (I); or a pharmaceutical acid addition salt thereof; and of formula II (II); or a pharmaceutical salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.

  本发明涉及一种化学式I（I）的选择性雌激素受体调节剂；或其药用酸盐；以及化学式II（II）的化合物；或其药用盐；可用于治疗子宫内膜异位症和/或子宫平滑肌瘤。
• PAI-1 INHIBITOR
  申请人：Yamaguchi Youichi

  公开号：US20090312315A1

  公开（公告）日：2009-12-17

  The compound represented by the following formula (I) and the like have PAI-1 inhibition activity; wherein: R 1 represents a C 6-10 aryl group which may be substituted or the like; T represents a single bond or the like; m represents 0 or 1; when m is 0, G represents —N—C(═O)—CO 2 H or the like; when m is 1, G represents an oxygen atom or the like; R 2 represents a C 6-10 aryl group which may be substituted or the like; E represents the following formula (II) wherein one of R 31 , R 32 , R 33 and R 34 represents the formula R 1 -T-, each of the other three independently represents a hydrogen atom or the like, and R 35 represents the formula —X—Y′, a hydrogen atom or the like; X represents —CH 2 — or the like; Y′ represents a carboxy group or the like; M represents a single bond or the like.

  以下公式（I）表示的化合物及类似化合物具有PAI-1抑制活性；其中：R1代表可能被取代的C6-10芳基或类似基团；T代表单键或类似键；m代表0或1；当m为0时，G代表—N—C(═O)—CO2H或类似基团；当m为1时，G代表氧原子或类似基团；R2代表可能被取代的C6-10芳基或类似基团；E代表以下公式（II），其中R31、R32、R33和R34中的一个代表公式R1-T-，其余三个分别独立地代表氢原子或类似基团，R35代表公式—X—Y′，氢原子或类似基团；X代表—CH2—或类似基团；Y′代表羧基或类似基团；M代表单键或类似键。
• [EN] BIPHENYL DERIVATIVES<br/>[FR] DÉRIVÉS DE BIPHÉNYLE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2021209473A1

  公开（公告）日：2021-10-21

  The invention relates to a compound of formula (I) wherein R1-R3 are as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

  本发明涉及一种式（I）的化合物，其中R1-R3如描述和权利要求中所定义。该式（I）的化合物可用作药物。